Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta…

Overview of attention for article published in Frontiers in immunology, July 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 3 X users
facebook: 1 Facebook page

reddit: 2 Redditors

Readers on

mendeley: 2 Mendeley

Summary X Facebook Reddit

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,098 followers.

RT @MLPOncoData: Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy f…

14 Aug 2024

Reply Repost Favourite

Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network #metaanalysis https://t.co/NYA2tdsjxV https://t.co/ML67I2ML5

14 Aug 2024

Reply Repost Favourite

Una recente metanalisi su 2878 pazienti suggerisce che il beneficio a lungo termine della immunochemioterapia di prima linea nel NSCLC, rispetto alla semplice immunoterapia, sia limitato ai casi con PD-L1 basso (1%-49%). https://t.co/PUcAG1Avai

08 Aug 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.